Blog | HemaCare

NK Cell Clinical Trial Begins for Incurable Cancer

Jul 16, 2019 10:12:00 AM / by Stacy Matthews Branch, DVM, PhD posted in Cancer, Immunotherapy, NK Cells

0 Comments

New tests begin in the United States using stem cell-derived natural killer cells to help patients suffering from incurable cancer.

Curing the incurable is an ongoing and top endeavor in medical research. This is particularly true for the various forms of cancer that are difficult to treat. The investigation and use of immunotherapy as an option for the treatment of different forms of cancer continues to increase. The main immunotherapeutic approach to cancer involves harvesting stem cells from the patient or a donor. Given the logistics, cost, and time this approach takes, the development of a strategy or cell products that can be used on demand is much desired.

Read More

How Transplanted Human Bone Marrow Cells May Improve ALS Therapy

Jul 9, 2019 10:07:00 AM / by Stacy Matthews Branch, DVM, PhD posted in Bone Marrow, CNS/Neurodegeneration

0 Comments

While no cure exists for ALS, researchers are finding ways to use unmodified human bone marrow CD34+ cells for spinal restoration.

The renowned physicist Stephen Hawking influenced how countless scientists worldwide view the universe. He also demonstrated his remarkable ability to survive amyotrophic lateral sclerosis (ALS) for 55 years. He is thought to be the longest survivor of ALS. According to the ALS Association, 50% of those with ALS survive for about 3 years after diagnosis, 20% survive for 5 or more years, and 10% survive for 10 years or more. There is no cure for ALS, and therapies that can slow or delay progression, decrease symptoms, and repair damaged spinal-cord tissue are continuously sought.

Read More

New HemaCare Publication Stipulates the Need for Healthy Donor Tissue

Jul 2, 2019 8:50:00 AM / by Nancy Andon, MSc posted in Apheresis, Cell Therapy

0 Comments

HemaCare has just announced the publication of their latest article in the popular stem cell industry periodical BioInformant. [1] The article focuses on the need for healthy donor starting material to keep up with growing demands in the cell and gene therapy industry.

Read More

Better Immunotherapy Research Needed for Elderly Lung Cancer Patients

Jun 25, 2019 10:03:00 AM / by Stacy Matthews Branch, DVM, PhD posted in Cancer, Immunotherapy

0 Comments

Varied responses to immunotherapy among elderly lung cancer patients reveal the need for more age-inclusive research and clinical trials.

The proportion of the U.S. population that is over 65 years of age has risen. Almost 50 million people are in this age range, a result of medical advancements which improve survival. However, cancer incidence has increased in this same age-group. More specifically, the 75 to 84-year-old age group has the highest percentage of cancer deaths. This increased incidence of cancer in the elderly may be associated with changes that occur in the immune system with advancing age.

Read More

HemaCare Starting Material Provides Real-Time Data on Therapeutic Cell Quality

Jun 18, 2019 10:04:00 AM / by Nancy Andon, MSc posted in Cell Therapy, Cell Therapy Manufacturing

0 Comments

Scientists at the Cell and Gene Therapy Catapult in the U.K. cite using HemaCare leukopaks to study a new method of scrutinizing cellular quality markers during cell therapy bioprocessing. [1]

The publication represents a collaborative effort among scientists developing cellular therapies in the United States and Canada as well as in the U.K. They are working together to solve a key issue; how to ensure the consistent high quality of their living products.

Read More

Subscribe Here!

Posts by Topic

see all

Recent Posts